Monitor future clinical trial results and regulatory developments for the asthma diagnostic platform, as successful validation could expand the company's market beyond lung cancer diagnostics.
Price Chart
Executive Summary
BioAffinity Technologies, Inc. announced the presentation of a scientific poster at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 annual meeting, detailing research on its diagnostic platform for identifying optimal therapies for asthma and COPD patients. The research demonstrates the technology's ability to identify drug antibody receptors in sputum for leading asthma therapies.
Key Facts
- Presented a poster titled 'Sputum as a Diagnostic Tool for the Treatment of Asthma' at the AAAAI 2026 annual meeting.
- Research shows the company's diagnostic platform can identify antibody drug receptors in sputum for dupilumab and benralizumab, two leading asthma therapies.
- The technology aims to assist physicians in matching asthma and COPD patients with effective therapies and monitoring inflammatory changes over time.
- The platform is already used in the company's commercial test, CyPath® Lung, for early detection of lung cancer.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- The research is still in the early stages and may not lead to a commercially viable product.
- The company faces competition from other diagnostic firms developing similar technologies.
- The company's small market cap ($1M) indicates high financial risk and potential volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-008723 |
| Exhibit: ex99-1.htm | 0001493152-26-008723 |
| Document: 0001493152-26-008723-index-headers.html | 0001493152-26-008723 |
| Document: 0001493152-26-008723-index.html | 0001493152-26-008723 |
| Document: 0001493152-26-008723.txt | 0001493152-26-008723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers